HealthTech Buyers Are Pricing Compliance Before the Rules Agree With Each Other

A three-regime problem, not one

Deal teams evaluating AI-enabled diagnostics and devices in the €25 million to €250 million range have started treating “AI Act readiness” as a quantifiable asset, something a target either has or must build. The instinct is reasonable. The execution is getting ahead of the facts, because there is no single global answer to what an AI-enabled medical device’s documentation needs to show.

In the US, the FDA’s recent clearances make the standard concrete rather than aspirational. Caristo’s de novo authorization for its coronary inflammation tool and DeepHealth’s 510(k) clearance for AI-driven breast ultrasound reporting both cleared review on the strength of evidence architecture built specifically for FDA’s pathway, not a generic transparency claim (MedTech Dive, MedTech Dive). DeepHealth’s own account of the clearance underscores how narrowly the submission was built around FDA’s specific evidentiary expectations for automation claims in breast imaging (HIT Consultant).

The EU is running a parallel but not identical track. Most EU AI Act provisions took effect in August 2026, layered on top of MDR/IVDR, which remains the operative certification regime for AI-enabled devices in the near term (healthcare.digital). Meanwhile China has been tightening its own regulatory approach to AI in life sciences on a separate track entirely, with compliance obligations that do not map cleanly onto either the US or EU frameworks (HLC).

A technical file built to satisfy a Notified Body under MDR does not automatically satisfy FDA’s evidentiary bar, and neither automatically satisfies Chinese regulators. Buyers assessing any target with cross-border ambitions are pricing a single jurisdiction’s paperwork as if it were portable. It usually is not.

The hype check

There is a useful cautionary parallel already playing out next door. AI drug discovery has attracted roughly $8.9 billion in capital against zero FDA approvals to date, a gap that analysts are now calling out directly as a bill coming due (Clinical Trial Vanguard). The lesson transfers to devices. Pricing “AI Act interpretability readiness” into a valuation is a bet on how EU enforcement will eventually treat clinical decision support tools, not a certainty grounded in settled precedent. Capital markets have already shown they can run well ahead of regulatory outcomes in adjacent AI health categories.

What this changes for deal teams

Diligence on a cross-border healthtech target needs to stop asking whether the documentation satisfies one regulator and start asking whether it is portable across regimes. Ask which pathway the technical file was actually built for. Ask what it would take to re-paper it for FDA, for a Notified Body, or for a Chinese regulator, and prices that rework into the model rather than assuming compliance is a fixed, transferable asset.

The certificate a target holds today tells you which regulator it satisfied first. It does not tell you what the other two will demand.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. Core argument that regulatory compliance is jurisdiction-specific and non-portable is sound and well-supported by concrete FDA clearance examples, though the claim that buyers are systematically mispr
Source & Claim Verification	Qwen · local	cleared. Most factual claims are supported by citations, but a few lines lack specific references, such as the assertion about the EU AI Act provisions taking effect in August 2026.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the divergent regulatory expectations of ISO 42001, EU AI Act, FDA, and MDR/IVDR but does not explicitly address ISO 42001’s requirements for AI management systems.
Technical Accuracy	Llama	cleared. The article accurately highlights the complexities and differences in regulatory requirements for AI-enabled medical devices across US, EU, and Chinese jurisdictions.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and counters potential vendor hype by highlighting the lack of regulatory harmonization and the overvaluation of single-jurisdiction compliance, drawing a strong pa
Novelty & Non-Duplication	Grok	held. Competent wire synthesis of recent FDA clearances plus multi-regime friction, but the core diligence claim is an incremental extension of the outlet’s existing €25–250M healthtech buyer-checklist fran
Validation	DeepSeek	cleared. The central claim that buyers are mistakenly pricing single-jurisdiction compliance as a portable asset is strongly validated by cited regulatory divergence between the US FDA, EU MDR/IVDR/AI Act, and

Sources cited: 14. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.